New Antibody Enters Human Trials for Autoimmune Disease
The first-in-human ATTRACT study of ATG-201 has begun in China and Australia, with clinical results still years from any approval decision.
Updated on Nov. 6, 2026 in Biotech

Antengene has dosed the first patient in China in the Phase I ATTRACT study of ATG-201, a CD19 × CD3 bispecific T-cell engager antibody. The study is being conducted in China and Australia, and the candidate remains in clinical research, not approved for use.
Why it matters
ATG-201 is aimed at refractory B cell-mediated autoimmune diseases, where current options have low remission rates and high relapse risk. UCB holds worldwide exclusive rights to further develop, manufacture, and commercialize the candidate, which signals the drug is being positioned for a larger global development path.
ATG-201 is a bispecific antibody that binds CD3 on T cells and CD19 on B cells, using steric hindrance masking technology to target CD19-expressing B cells for elimination. Antengene's portfolio includes 35 investigational new drug approvals across the U.S. and Asia, but no clinical efficacy or safety measurements for ATG-201 have been published yet.
The players
Antengene
A Shanghai and Hong Kong-based biopharmaceutical company developing oncology and immunology candidates, including ATG-201.
UCB
A global biopharmaceutical company that holds worldwide exclusive rights to develop, manufacture, and commercialize ATG-201.
Prof. Zhanguo Li
Principal investigator of the ATTRACT study at Peking University People's Hospital.
The details
ATG-201 is a bispecific T-cell engager, meaning one antibody that physically links two cell types: it binds CD3 on T cells (the immune system's killer cells) and CD19 on B cells (immune cells that produce antibodies). By bringing these together, it aims to direct the body's own T cells to eliminate the B cells that drive the disease. The candidate incorporates steric hindrance masking technology, a design approach intended to limit the drug's activity to where it is needed.
Timeline
Nov. 6, 2026: Antengene announced the first patient was dosed in the ATTRACT study.
The Tech Race
CD19-directed T-cell engagers have been developed mainly for B cell malignancies, and ATG-201 tests whether the same class can be applied to autoimmune conditions. Its differentiation rests on the steric hindrance masking design and on UCB's global commercial rights, both still unproven in clinical data.
ATG-201 is still in Phase I testing and is not available to patients, and no timeline for approval has been announced. Patients with refractory B cell-mediated autoimmune diseases would only be affected if the trial and later development succeed.
The takeaway
The key trajectory signal is whether ATG-201 can deliver durable B cell depletion with acceptable safety in autoimmune patients, a question the ATTRACT study is designed to begin answering. Watch for the recommended Phase II dose and early safety data from the Dose Escalation portion of the trial.
Further reading
For background on the drug development pipeline behind candidates like this, see the Biotech section.
Source note: This article includes information reported by Macau Business.


